[1] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[2] Sarin S K, Choudhury A, Sharma M K, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update . Hepatol Int, 2019, 13(4): 353-90.
[3] 李新婷, 姚瑶, 邓家玉, 等. 双重血浆分子吸附系统联合半量血浆置换治疗肝衰竭的短期疗效分析. 新疆医科大学学报, 2022, 45(2): 155-159.
[4] Park J H, Her C, Min H K, et al. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs, 2015, 38(11): 595-599.
[5] 焦思, 王萌, 孙彦奇. 非生物型人工肝支持技术治疗的应用进展. 国际护理学杂志, 2021, 22(3): 572-576.
[6] Olson S T, Richard B, Izaguirre G, et al. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors . Biochimie, 2010, 92(11): 1587-1596.
[7] Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol, 2012, 35(207): 43-61.
[8] 季闽春, 钱庆庆, 杨耀芳. 肝素诱导的血小板减少症的病因、诊断和治疗研究进展. 中国临床药理学杂志, 2007, 23(6): 461-465.
[9] 高飞, 李烨, 曾晖,等. 不同肝素钠抗凝治疗方案在肝衰竭患者血浆置换中的比较研究. 中国现代医学杂志, 2022, 32(3): 70-73.
[10] 汤汝佳, 胡彦明, 姚红宇, 等. 低分子肝素在人工肝治疗肝衰竭患者时的临床应用. 肝脏, 2023, 28(9): 1024-1027.
[11] Kujovich J L. Coagulopathy in liver disease: a balancing act. Hematology, 2015, 2015: 243-249.
[12] Guo X, Wu F, Guo W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res, 2020, 48(6): 300060520932053.
[13] 张洁, 赵成燕, 郑嵘炅, 等. 不同抗凝药物在双重胆红素吸附联合血浆置换对肝衰竭的治疗效果及安全性比较. 新疆医科大学学报, 2022, 45(2): 150-154.
[14] 朱宝焕, 吴玲霞, 冯晓梅, 等. 低分子肝素和凯时在MARS人工肝治疗中的联合应用及护理. 国际护理学杂志, 2008, 27(2): 148-149,e215.
[15] 李百彦, 张萍. 磺达肝癸钠和依诺肝素在75岁以上急性冠脉综合征患者中的应用. 中华现代护理杂志, 2012, 18(19): 2271-2273.
[16] Nilius H, Kaufmann J, Cuker A, et al. Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. Am J Hematol, 2021, 96(7): 805-815.
[17] 毕智敏, 余毅. 血液净化抗凝治疗的新进展. 中华临床医师杂志(电子版), 2015, 24(13): 2469-2472.
[18] Jeske W, Walenga J M, Lewis B E, et al. Pharmacology of argatroban. Expert Opin Investig Drugs, 1999, 8(5): 625-654.
[19] 曹芳芳, 张海涛, 冯雪,等. 阿加曲班在肾脏替代治疗中应用的Meta分析. 中国医学科学院学报, 2013, 35(6): 667-671.
[20] Yarbrough P M, Varedi A, Walker A, et al. Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by child-pugh class C liver disease. Ann Pharmacother, 2012, 46(11): e30.
[21] 邹鹏飞, 屠明敏, 戴霞红, 等. 小剂量阿加曲班与低分子肝素在李氏人工肝治疗中抗凝疗效及安全性比较. 中华临床感染病杂志, 2019,16 (3): 201-205.
[22] 潘鑫, 谢攀, 卓燕, 等. 枸橼酸钠抗凝在不同血液净化模式中的应用. 中国血液净化, 2020, 19(8): 543-546.
[23] Kirwan C J, Hutchison R, Ghabina S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. Blood Purif, 2016, 42(4): 349-355.
[24] Wu M Y, Hsu Y H, Bai C H, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis, 2012, 59(6): 810-818.
[25] Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med, 2003, 31(10): 2450-2455.
[26] Meijers B, Laleman W, Vermeersch P, et al. A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care, 2012, 16(1): R20.
[27] Qin G, Shao J G, Wang B, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore), 2014, 93(28): e338.
[28] Larsen F S, Schmidt L E, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol, 2016, 64(1): 69-78.
[29] Honore P M, Mugisha A, David C, et al. In severe liver disease, citrate can be used safely: the question remains-by which mechanism. Crit Care, 2020, 24(1): 63.
[30] Honore P M, De Bels D, Redant S, et al. Inducible metabolic pathway for citrate metabolism in case of major liver dysfunction: fact or fiction? Crit Care, 2019, 23(1): 166.
[31] Yuan S, Qian Y, Tan D, et al. Therapeutic plasma exchange: A prospective randomized trial to evaluate 2 strategies in patients with liver failure. Transfus Apher Sci, 2018, 57(2): 253-258.
[32] Lee Y K, Lee H W, Choi K H, et al. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One, 2014, 9(10): e108737.
[33] Willers A, Arens J, Mariani S, et al. New trends, advantages and disadvantages in anticoagulation and coating methods used in extracorporeal life support devices. Membranes (Basel), 2021, 11(8):342-348.
[34] Hwang S D, Hyun Y K, Moon S J, et al. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs, 2013, 36(3): 208-216.
[35] Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis, 1985, 15(3): 164-168.
[36] Fuse I, Higuchi W, Toba K, et al. Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets, 1999, 10(4): 212-218.
[37] 王新月, 周莉, 董金玲,等. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究. 实用肝脏病杂志, 2023, 26(6): 843-846.
[38] Lim J Y, Kim J B, Choo S J, et al. Anticoagulation during extracorporeal membrane oxygenation; Nafamostat mesilate versus heparin. Ann Thorac Surg, 2016, 102(2): 534-539.
[39] Nakae H, Fukuda H, Okuyama M, et al. Selective plasma exchange for critically ill patients accompanied with thrombocytopenia. Ther Apher Dial, 2016, 20(4): 339-341. |
